Download or read book Identification of Novel Biomarkers and Therapeutic Targets Regulating Metastasis of Triple Negative Breast Cancer written by Shih-Hsuan Chan and published by . This book was released on 2019 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Identification of Novel Biomarkers and Therapeutic Strategies in Triple Negative Breast Cancer written by Ahmed Elkashif and published by . This book was released on 2021 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Predictive Prognostic Biomarkers and Therapeutic Targets in Triple Negative Breast Cancer written by Shengtao Zhou and published by Frontiers Media SA. This book was released on 2021-12-01 with total page 111 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Breast Cancer From Bench to Personalized Medicine written by Saima Shakil Malik and published by Springer Nature. This book was released on 2022-05-14 with total page 534 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides detailed information on the etiology, pathogenesis, diagnosis, prognosis, and treatment strategies for breast cancer. The first section of the book presents epidemiology, risk factors, histopathological, immunohistochemistry, and molecular subtypes of breast cancer based on the receptor status. It also discusses the association of breast cancer with other hormone-sensitive cancers. The second section of the book covers cover BRCA1 and BRCA2-associated breast carcinogenesis, early-stage progression of breast cancer, and noninvasive biomarkers for the early detection of breast cancer. It also discusses the role of epigenetic modifications and non-coding RNAs in breast cancer metastasis and explores these as the biomarkers and therapeutic targets for breast cancer therapy. Further, it discusses the role of fibrinolytic mechanisms and circulating tumor cells in breast cancer diagnosis, prognosis, and treatment. The book also provides an update on oral poly(ADP-ribose) polymerase (PARP) inhibitors to treat breast cancer. Finally, it offers potential new options for personalized therapies for breast cancer patients, including optimizing drug dosage and identifying genetic changes associated with cancer symptom occurrence and severity.
Download or read book Identification of Kinase Biomarkers and Therapeutic Targets in Triple negative Breast Cancer written by Bo Li and published by . This book was released on 2017 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Biomarkers in Breast Cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2008-01-17 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Download or read book Circulating Tumor Cells in Breast Cancer Metastatic Disease written by Roberto Piñeiro and published by Springer Nature. This book was released on 2020-04-17 with total page 177 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is aimed to summarise the key aspects of the role of circulating tumour cells (CTCs) in breast cancer, with special attention to their contribution to tumour progression and establishment of metastatic disease. We aim to give a clear overview of the knowledge about CTCs, framed in the context of breast cancer, by analysing basic and clinical research carried out so far. In a broader sense, we will address what are the main clinical needs of this disease based on its molecular heterogeneity (subtypes) and lay out the knowledge and understanding that CTCs are giving about it and how they are contributing and can still improve the better monitoring and management of breast cancer patients. We will discuss the evidences of the use of CTCs as a tool to monitor cancer progression and therapy response, based on the prognostic and predictive value they have, as well as a tool to unravel mechanisms of resistance to therapy and to identify new biomarkers allowing to predict therapy success. Moreover, we will analyse the main aspects of ongoing clinical trials and how they can contribute to determine the clinical utility of CTCs as a breast cancer biomarker. We will also touch upon general knowledge or basic notions of the biology of the metastatic process in epithelial cancers, in order to understand the origin and biology of CTCs. In this sense, we will pay special attention to EMT (epithelial to mesenchymal transition), dormancy and minimal residual disease, three key aspects that determine the outcome of the disease. We will also cover general aspects on the isolation and characterization techniques applies to the study of CTCs, and also the possibilities that the study of CTCs, as a biomarker with biological function, is opening in terms of understanding the biology of metastatic cells and the identification of therapeutic targets based on the functional and molecular characterization of CTCs. Lastly, we will try to foresee the future of CTCs in terms of clinical application and implementation in the clinical routine.
Download or read book Novel Biomarkers in the Continuum of Breast Cancer written by Vered Stearns and published by Springer. This book was released on 2016-03-17 with total page 291 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment(s) for individual patients.
Download or read book Molecular Biology of Cancer written by Fiona Macdonald and published by Taylor & Francis. This book was released on 2004-06-02 with total page 296 pages. Available in PDF, EPUB and Kindle. Book excerpt: Molecular Biology of Cancer has been extensively revised and covers heredity cancer, microarray technology and increased study of childhood cancers. It continues to provide a detailed overview of the process which lead to the development and proliferation of cancer cells, including the techniques available for their study. It also describes the means by which tumor suppressor genes and oncogenes may be used in the diagnosis and in determining the prognosis of a wide variety of cancers, including breast, genitourinary, lung and gastrointestinal cancer.
Download or read book Epithelial Mesenchymal Plasticity in Cancer Metastasis written by Mohit Kumar Jolly and published by MDPI. This book was released on 2020-12-29 with total page 512 pages. Available in PDF, EPUB and Kindle. Book excerpt: Recent studies have highlighted that epithelial-mesenchymal transition (EMT) is not only about cell migration and invasion, but it can also govern many other important elements such as immunosuppression, metabolic reprogramming, senescence-associated secretory phenotype (SASP), stem cell properties, therapy resistance, and tumor microenvironment interactions. With the on-going debate about the requirement of EMT for cancer metastasis, an emerging focus on intermediate states of EMT and its reverse process mesenchymal-epithelial transition (MET) offer new ideas for metastatic requirements and the dynamics of EMT/MET during the entire metastatic cascade. Therefore, we would like to initiate discussions on viewing EMT and its downstream signaling networks as a fulcrum of cellular plasticity, and a facilitator of the adaptive responses of cancer cells to distant organ microenvironments and various therapeutic assaults. We hereby invite scientists who have prominently contributed to this field, and whose valuable insights have led to the appreciation of epithelial-mesenchymal plasticity as a more comprehensive mediator of the adaptive response of cancer cells, with huge implications in metastasis, drug resistance, tumor relapse, and patient survival.
Download or read book Identification of Novel Biomarkers and Targeting Tumor initiating Cell Clones of the Triple negative Breast Cancer Subtype written by Sidse Hickman Ehmsen and published by . This book was released on 2016 with total page 170 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book New Prognostic and Predictive Markers in Cancer Progression written by Susan Costantini Alfredo Budillon and published by MDPI. This book was released on 2021-02-12 with total page 294 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biomarkers are of critical medical importance for oncologists, allowing them to predict and detect disease and to determine the best course of action for cancer patient care. Prognostic markers are used to evaluate a patient’s outcome and cancer recurrence probability after initial interventions such as surgery or drug treatments and, hence, to select follow-up and further treatment strategies. On the other hand, predictive markers are increasingly being used to evaluate the probability of benefit from clinical intervention(s), driving personalized medicine. Evolving technologies and the increasing availability of “multiomics” data are leading to the selection of numerous potential biomarkers, based on DNA, RNA, miRNA, protein, and metabolic alterations within cancer cells or tumor microenvironment, that may be combined with clinical and pathological data to greatly improve the prediction of both cancer progression and therapeutic treatment responses. However, in recent years, few biomarkers have progressed from discovery to become validated tools to be used in clinical practice. This Special Issue comprises eight review articles and five original studies on novel potential prognostic and predictive markers for different cancer types.
Download or read book From Data to Bench to Bedside written by Erhan Bilal and published by . This book was released on 2010 with total page 112 pages. Available in PDF, EPUB and Kindle. Book excerpt: Understanding individualized breast cancer treatment options can help physicians care for their patients by careful selection of personalized therapies. The first steps towards this goal have already been taken by clinicians, with the frequent use of molecular and genetic biomarkers to classify breast cancer into categories which direct treatment. This thesis will propose new therapeutic targets for different breast cancer subtypes, as well as a new set of biomarkers that more efficiently predict hormone resistance in estrogen positive (ER+) breast tumors. A novel methodology for therapeutic target prediction will be proposed, based on a new paradigm called "gene centrality". In addition to being over-expressed, good therapeutic targets should have a high degree of connectivity in the tumor network. Gene centrality encompasses this concept by measuring the connectivity of genes in a network in which each edge is weighted by the level of over-expression of the target gene. Using this method, a series of high centrality SRC proto-oncogenes (LYN, YES1, HCK, FYN, and LCK) were identified in subsets of Basal-like and HER2+ breast cancers. The hypothesis that YES1 is a therapeutic target in breast cancer was experimentally tested. We found that Basal-like breast tumor cell lines showed a significant decrease in fitness upon silencing the expression of YES1. Another validated therapeutic target in breast cancer is the estrogen receptor ESR1, targeted by drugs such as Tamoxifen. However, a significant fraction (~30%) of ER+ cases doesnt́ respond well to this therapy. A novel outlier analysis method was applied to gene expression data from ER+ breast cancer patients to identify genes highly associated with Tamoxifen resistance. These included cell cycle genes as well as several chromosomal amplification sites. In addition to the well known HER2 amplicon on 17q12, we discovered that amplicons in 8q24.3, 8p11.2 and 17q21.33-q25.1 correlate strongly with early distant metastasis and poor long term survival. As independent biomarkers for Tamoxifen resistance, together these chromosomal regions are predictive for ~75% of patients that suffer early disease relapse.
Download or read book Non coding RNAs in Breast Cancer written by Wenwen Zhang and published by Frontiers Media SA. This book was released on 2022-01-06 with total page 158 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Targeted Therapies in Breast Cancer written by Gw Sledge and published by Clinical Pub. This book was released on 2012-06 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.
Download or read book Specialist Training in Oncology E Book written by Thankamma V Ajithkumar and published by Elsevier Health Sciences. This book was released on 2011-10-28 with total page 409 pages. Available in PDF, EPUB and Kindle. Book excerpt: This textbook of oncology is aimed at specialist registrars in the early phase of their training. The basic concepts of cancer practice is touched upon in undergraduate and junior postgraduate years, but new trainees frequently seek additional resources to boost their knowledge in the field of Oncology. This title offers a concise account of the multidisciplinary management of common cancers and cancer-related problems appropriate to doctors at the start of their careers in this specialty. The content of the book is based on latest available evidence and reflects the training guidelines. Readable and concise style, aimed at the beginner in this specialty. Well illustrated in colour with graphics, clinical photographs and radiographs. Section on research methodology. Approachable design in the ‘Specialist Training in...’ series style.
Download or read book Heat Shock Proteins in Cancer written by Stuart K. Calderwood and published by Springer Science & Business Media. This book was released on 2007-09-09 with total page 399 pages. Available in PDF, EPUB and Kindle. Book excerpt: Heat shock proteins are emerging as important molecules in the development of cancer and as key targets in cancer therapy. These proteins enhance the growth of cancer cells and protect tumors from treatments such as drugs or surgery. However, new drugs have recently been developed particularly those targeting heat shock protein 90. As heat shock protein 90 functions to stabilize many of the oncogenes and growth promoting proteins in cancer cells, such drugs have broad specificity in many types of cancer cell and offer the possibility of evading the development of resistance through point mutation or use of compensatory pathways. Heat shock proteins have a further property that makes them tempting targets in cancer immunotherapy. These proteins have the ability to induce an inflammatory response when released in tumors and to carry tumor antigens to antigen presenting cells. They have thus become important components of anticancer vaccines. Overall, heat shock proteins are important new targets in molecular cancer therapy and can be approached in a number of contrasting approaches to therapy.
